LILLY Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LILLY, and when can generic versions of LILLY drugs launch?
LILLY has one hundred and five approved drugs.
There is one US patent protecting LILLY drugs.
There are thirty patent family members on LILLY drugs in twenty-five countries and eighty-six supplementary protection certificates in thirteen countries.
Drugs and US Patents for LILLY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | CYMBALTA | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 021427-004 | Aug 3, 2004 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lilly | ALPHALIN | vitamin a palmitate | CAPSULE;ORAL | 080883-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lilly | DROLBAN | dromostanolone propionate | INJECTABLE;INJECTION | 012936-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lilly | PROPYLTHIOURACIL | propylthiouracil | TABLET;ORAL | 006213-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lilly | KEFUROX IN PLASTIC CONTAINER | cefuroxime sodium | INJECTABLE;INTRAVENOUS | 062590-001 | Jan 10, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lilly | ILOSONE | erythromycin estolate | CAPSULE;ORAL | 061897-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lilly | NEBCIN | tobramycin sulfate | INJECTABLE;INJECTION | 062008-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LILLY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | 5,641,790 | ⤷ Try a Trial |
Lilly | DECABID | indecainide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019693-001 | Dec 29, 1989 | 4,389,393 | ⤷ Try a Trial |
Lilly | ALIMTA | pemetrexed disodium | POWDER;INTRAVENOUS | 021462-002 | Sep 7, 2007 | 5,217,974*PED | ⤷ Try a Trial |
Lilly | CIALIS | tadalafil | TABLET;ORAL | 021368-003 | Nov 21, 2003 | 6,821,975*PED | ⤷ Try a Trial |
Lilly | CIALIS | tadalafil | TABLET;ORAL | 021368-002 | Nov 21, 2003 | 6,943,166*PED | ⤷ Try a Trial |
Lilly | PROZAC | fluoxetine hydrochloride | SOLUTION;ORAL | 020101-001 | Apr 24, 1991 | 4,314,081*PED | ⤷ Try a Trial |
Lilly | SYMBYAX | fluoxetine hydrochloride; olanzapine | CAPSULE;ORAL | 021520-005 | Dec 24, 2003 | 6,960,577 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LILLY drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-release Capsules | 40 mg | ➤ Subscribe | 2012-05-10 |
➤ Subscribe | Capsules | 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg | ➤ Subscribe | 2005-01-10 |
➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2005-11-01 |
➤ Subscribe | For Injection | 2 g/vial | ➤ Subscribe | 2007-08-24 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-02-04 |
➤ Subscribe | For Injection | 750 mg/vial | ➤ Subscribe | 2016-10-06 |
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2008-10-14 |
➤ Subscribe | Delayed-release Capsules | 20 mg, 30 mg and 60 mg | ➤ Subscribe | 2008-08-04 |
➤ Subscribe | Capsules | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | ➤ Subscribe | 2007-05-29 |
➤ Subscribe | Capsules | 3 mg/25 mg | ➤ Subscribe | 2008-05-08 |
➤ Subscribe | For Injection | 1g/vial | ➤ Subscribe | 2005-11-14 |
➤ Subscribe | For Injection | 100 mg/vial | ➤ Subscribe | 2008-07-01 |
➤ Subscribe | For Injection | 1000 mg/vial | ➤ Subscribe | 2012-06-27 |
➤ Subscribe | Injection | 250 mcg/mL, 2.4 mL prefilled Pen | ➤ Subscribe | 2015-07-27 |
➤ Subscribe | Tablets | 5 mg, 10 mg and 20 mg | ➤ Subscribe | 2007-11-21 |
International Patents for LILLY Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 1732628 | ⤷ Try a Trial |
South Korea | 20060131946 | ⤷ Try a Trial |
Poland | 1732629 | ⤷ Try a Trial |
Croatia | P20191242 | ⤷ Try a Trial |
Montenegro | 03411 | ⤷ Try a Trial |
Japan | 2007530241 | ⤷ Try a Trial |
Australia | 2005231731 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for LILLY Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0247633 | 62/1997 | Austria | ⤷ Try a Trial | PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107 |
0122707 | SPC/GB95/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GEMCITABINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY- ACCEPTABLE SALT; REGISTERED: NL RVG17854 19950327; UK 00006/0301 19951026; UK 00006/0302 19951026 |
0721777 | SPC/GB04/033 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ATOMOXETINE, OPTIONALLY IN THE FORM OF A SALT, SUCH AS THE HYDROCHLORIDE; REGISTERED: UK PL 00006/0374 20040527; UK PL 00006/0375 20040527; UK PL 00006/0376 20040527; UK PL 00006/0377 20040527; UK PL 00006/0378 20040527; UK PL 00006/0379 20040527 |
0740668 | PA2003001 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328 |
3141251 | 301099 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016 |
1480644 | 16C1019 | France | ⤷ Try a Trial | PRODUCT NAME: ASSOCIATION OU MELANGE PHARMACEUTIQUE RENFERMANT EN TANT QU'INGREDIENTS ACTIFS:(1) LA CEFTAZIDIME OU UN DES SES SELS ET (2) L'AVIBACTAM OU UN DE SES SELS; REGISTRATION NO/DATE: EU/1/16/1109 20160628 |
0273658 | 2005C/001 | Belgium | ⤷ Try a Trial | PRODUCT NAME: CHLORHYDRATE DE DULOXETINE; REGISTRATION NO/DATE: EU/1/04/280/001 20040811 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.